Key Highlights
● Arcturus jumped on Friday, trading at about $14.10 by mid-morning, as an analyst call met an mRNA rally.
● Leerink Partners analyst Lili Nsongo kept an Outperform rating and raised the price target to $19 from $13.
● Moderna jumped $28.00 to $225.00 on the day it officially entered the Nasdaq-100, and BioNTech, Novavax and Vaxcyte also climbed.
● Arcturus is a clinical-stage company developing mRNA medicines and vaccines, including self-amplifying mRNA technology and rare-disease treatments.
Arcturus Therapeutics (NASDAQ:ARCT) jumped on Friday, trading at about $14.10 by mid-morning, as two forces worked in its favor. Leerink Partners analyst Lili Nsongo kept an Outperform rating on the stock and raised the price target to $19 from $13. At the same time, a broad rally in messenger RNA, or mRNA, companies swept the biotech sector.
A higher price target does not guarantee anything, but it signals that an analyst sees more value in a company than before. Leerink's new target sits well above where Arcturus was trading on Friday.
The cancer-vaccine spark
The sector rally followed a media report that the National Institutes of Health plans a public-private campaign, starting in December, to fast-track cancer Vaccine research. According to the report, the initial focus would be pancreatic, liver and colorectal cancers plus some childhood tumors, with the aim of repeating the success of the Covid-19 vaccine effort.
That message resonated with mRNA developers. Moderna (NASDAQ:MRNA) jumped $28.00 to $225.00, its highest close since 2021, on the same day it officially entered the Nasdaq-100. BioNTech (NASDAQ:BNTX), Novavax (NASDAQ:NVAX) and Vaxcyte (NASDAQ:PCVX) also climbed, and larger drugmakers such as Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Gilead Sciences (NASDAQ:GILD) moved higher.
What Arcturus does
Arcturus is a clinical-stage company developing mRNA medicines and vaccines, including self-amplifying mRNA technology designed to produce a stronger response from a smaller dose. Its work spans infectious-disease vaccines and treatments for rare diseases. As a smaller player in the mRNA field, its shares tend to move sharply when sentiment toward the technology changes.
That cuts both ways. The NIH initiative, as reported, is still in the planning stage, and it is not yet known which companies might participate or how funding would flow. For now, the rally reflects enthusiasm for the technology as a whole rather than any specific contract or award for Arcturus.
Health care in the lead
Health care was among the strongest sectors in the S&P 500 on Friday, helped by the vaccine rally and by Humana (NYSE:HUM)'s surge after new Medicare star ratings. The sector also ranked among the leaders for the week, alongside utilities, consumer staples and energy.
The broader market rose. The Nasdaq Composite gained 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54, about seven points below Tuesday's record close, and the Dow climbed 423.31 points to 51,654.95. The Russell 2000, home to many smaller biotechs, rose 12.85 points to 2,806.98 but still ended a fifth straight losing week.
Rates remain a challenge for development-stage drug companies that rely on outside funding. The 10-year Treasury Yield held near a 24-year high, and the Fed, which raised rates in September for the first time since 2023, has signaled more hikes may follow. Fed Governor Christopher Waller said: "For at least the near term, policy will be focused on the Inflation side of our mandate."
Official NIH Details and Arcturus Pipeline Updates Are the Next Items to Watch
Monday, October 12 is Columbus Day, with stocks open and bonds closed. September consumer prices arrive Wednesday, October 14, with producer prices and retail sales on Thursday. Bank Earnings run from October 13 to 16, and the Fed meets on October 27 and 28. For Arcturus, official details of the NIH-linked initiative ahead of its expected December launch and any pipeline update are the next items to watch.






Please wait processing your request...